OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Vilobelimab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors InflaRx
- 28 Jun 2024 According to ClinicalTrial.gov record,Reason the study was stopped because Sponsor decided to stop the development of vilobelimab in cSCC and early terminates the IFX-1-P2.8 trial due to new alternative treatments for cSCC with high efficacy rates.
- 28 Jun 2024 Status changed from active, no longer recruiting to discontinued.
- 17 Jun 2024 This trial has been discontinued in Belgium and France, according to European Clinical Trials Database record.